Insider · CIK 0001990674
Allan Camaisa
Files at CLDI (Calidi Biotherapeutics, Inc.). First filing Dec 18, 2024, latest Dec 16, 2025.
In brief
Allan Camaisa files SEC Form 4 as CEO, chair, director, president and 10% owner at CLDI (Calidi Biotherapeutics, Inc.). Since Dec 18, 2024, Allan Camaisa has reported 0 open-market buys worth $0 and 2 open-market sells worth $17k, the latest filed on Dec 16, 2025.
A track record needs three past buys with six months of prices behind them; Allan Camaisa has 0, so none is measured yet.
The newest scored trade: sold $1,237 of CLDI on Dec 12, 2025, filed Dec 16, 2025, scored 15 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $1,237.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CLDI: Calidi Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | CLDIsell Calidi Biotherapeutics, Inc. | $1,237 850 shares | -1% | +9% from low-93% from high | |
| 30Weak | CLDIsell Calidi Biotherapeutics, Inc. | $16k 10,000 shares | -13% | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | CLDI Calidi Biotherapeutics, Inc. | SOpen-market sale Common Stockindirect: AJC Capital, LLC | -850 | $1.46 | $1,237 | 76,952 | Dec 16, 2025 |
| Dec 17, 2024 | CLDI Calidi Biotherapeutics, Inc. | SOpen-market sale Common Stock | -10,000 | $1.62 | $16k | 66,712 | Dec 18, 2024 |
| Dec 21, 2023 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +100,000 | - | - | 100,000 | Jan 4, 2024 |
Questions about Allan Camaisa
Answered from the filings on this page, as of the latest one.
Is Allan Camaisa buying or selling?
In the last 12 months Allan Camaisa reported 0 open-market buys worth $0 and 1 open-market sell worth $1,237 on SEC Form 4; the latest was sold $1,237 of CLDI on Dec 12, 2025. Grants, option exercises and tax withholding are not counted.
How did Allan Camaisa's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Allan Camaisa has 0.
Where does Allan Camaisa file Form 4?
Allan Camaisa has filed Form 4 at CLDI (Calidi Biotherapeutics, Inc.) as CEO, President and Chairman. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.